John C. Bell

An integrated stress response regulates amino acid metabolism and resistance to oxidative stress.

CHD1 associates with NCoR and histone deacetylase as well as with RNA splicing proteins.

Getting oncolytic virus therapies off the ground.

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Vesicular stomatitis virus: re-inventing the bullet.

Activating transcription factor 4 is translationally regulated by hypoxic stress.

Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy.

Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR.

Internal translation initiation mediated by the angiogenic factor Tie2.

Recent progress in the battle between oncolytic viruses and tumours.

Internal ribosome entry site-mediated translation of Apaf-1, but not XIAP, is regulated during UV-induced cell death.

A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization.

Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress.

Matrix protein of Vesicular stomatitis virus harbours a cryptic mitochondrial-targeting motif.

Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.

Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

Novel therapeutic target: the PERKs of inhibiting the integrated stress response.

Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer.

Oncolytic viruses: what's next?

Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene.

Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow.

Intercellular trafficking of VP22, a herpes simplex virus type 1 tegument protein.

Matrix protein mediated shutdown of host cell metabolism limits vesicular stomatitis virus-induced interferon-alpha responses to plasmacytoid dendritic cells.

Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?

Translational control of the innate immune response through IRF-7.

Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.

Complex rearrangement of chromosomes 19, 21, and 22 in Ewing sarcoma involving a novel reciprocal inversion-insertion mechanism of EWS-ERG fusion gene formation: a case analysis and literature review.

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop.

Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.

A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication.

Efficacy of systemically administered mutant vesicular stomatitis virus (VSVDelta51) combined with radiation for nasopharyngeal carcinoma.

Development of targeted oncolytic virotherapeutics through translational research.

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis.

MicroRNAs fine-tune oncolytic viruses.

Diplomatic immunity: turning a foe into an ally.

Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.

Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.

Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death.

Intelligent design: combination therapy with oncolytic viruses.

Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice.

Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.

Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.

Novel oncolytic viruses: riding high on the next wave?

United virus: the oncolytic tag-team against cancer!

Synergistic interaction between oncolytic viruses augments tumor killing.

Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.

A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.

Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval.

Identification of genetically modified Maraba virus as an oncolytic rhabdovirus.

Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus.

Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.

Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors.

Targeting tumor vasculature with an oncolytic virus.

Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.

Thunder and lightning: immunotherapy and oncolytic viruses collide.

Chromosomal position effects are linked to sir2-mediated variation in transcriptional burst size.

Viral quantitative capillary electrophoresis for counting intact viruses.

Targeted and Armed Oncolytic Poxviruses for Cancer: The Lead Example of JX-594.

A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

A selectable and excisable marker system for the rapid creation of recombinant poxviruses.

Interfering with tumor pathways that augment viral oncolysis.

Oncolytic viruses: smart therapeutics for smart cancers.

Suppression of PKR promotes network excitability and enhanced cognition by interferon-γ-mediated disinhibition.

Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: Potential role of human papilloma virus infection.

The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers.

Electrochemical sensing of aptamer-facilitated virus immunoshielding.

ORFV: A Novel Oncolytic and Immune Stimulating Parapoxvirus Therapeutic.

Aptamer-Based Viability Impedimetric Sensor for Viruses.

Electrochemical Differentiation of Epitope-Specific Aptamers.